Evaluation of Urinary Tract Infection following Corticosteroid Therapy in Patients with Multiple Sclerosis Exacerbation

Table 1

Baseline characteristics of the study population.

Parameter	OPT group	Control group	value
Age (mean ± SD)	30.57 ± 5	32.76 ± 7.09	0.207
Gender ratio (female/male)	19/9	16/12	0.687
Disease duration	2.60 ± 1.96	4.67 ± 4.48	0.174
DMDs before relapse n (%)
Glatiramer acetate	1	5	.084
Interferon beta 1b	0	1	1.000
Interferon beta 1a	8	6	0.537
Dimethyl fumarate	1	2	0.553
Fingolimod	2	1	0.553
No previous use of DMDs	16	13	0.422
EDSS (mean ± SD)	3.21 ± 1.40	3.28 ± 1.13	0.834
Marital status (married)	53.6%	71.4%	0.626
Urinary tract symptoms, n (%)	12 (42.9%)	8 (28.6%)	0.033

MS: multiple sclerosis; RRMS: relapsing-remitting multiple sclerosis; OPT: oral prednisone taper; SD: standard deviation; DMDs: Disease-Modifying Drugs; EDSS: Expanded Disability Status Scale.